![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Pfizer’s COVID-19 Vaccine Is More Than 90 Percent Effective
Pfizer’s COVID-19 Vaccine Is More Than 90 Percent Effective
![pfizerlogo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/pfizerlogo.gif?t=1576044507&width=430)
Pfizer announced that its COVID-19 vaccine candidate, BNT162, was more than 90 percent effective based on early data from 94 participants in a phase 3 trial.
The company remains on track to submit a request for an Emergency Use Authorization to the FDA in the third week of this month.
Pfizer, which is developing the vaccine along with Germany-based BioNTech, expects to manufacture up to 50 million doses of the vaccine in 2020 and up to 1.3 billion doses in 2021.
Upcoming Events
-
21Oct